Bailey T A, Wernery U, Samour J H, Naldo J L
National Avian Research Center, Veterinary Science Department, Abu Dhabi, United Arab Emirates.
J Zoo Wildl Med. 1998 Dec;29(4):441-50.
Adult houbara bustards (Chlamydotis undulata) and juvenile kori bustards (Ardeotis kori) were given four regimens of commercially available inactivated and live poultry paramyxovirus type 1 (PMV-1) vaccines. Immunologic response to vaccination was assessed by hemagglutination inhibition assay of serum. Kori bustards, to which a dose of 0.5 ml of a commercially available inactivated vaccine for poultry had been administered intramuscularly (0.15 ml/kg body weight), failed to develop hemagglutinating antibodies, but antibody titers of low intensity and duration were detected following administration of a second and third subcutaneous dose of 2.0 ml vaccine per bird (0.40-0.45 ml/kg). In subsequent trials, when inactivated vaccine was administered subcutaneously at 1.0 ml/kg body weight following two or four live vaccinations administered by the ocular route, juvenile kori bustards developed higher, more persistent titers of antibodies. Kori bustards given four live vaccinations followed by inactivated vaccine developed higher titers of longer duration compared with kori bustards given two live vaccines followed by inactivated vaccine. Antibody titers of kori bustards given inactivated vaccine were higher and more persistent than the antibody response to live vaccination. Houbara bustards, previously vaccinated with inactivated vaccine, that were given a booster dose of inactivated vaccine maintained high mean antibody titers (> or = log, 5) for 52 wk. The authors recommend that inactivated PMV-1 vaccine should be administered by subcutaneous injection of 1.0 ml/kg vaccine to bustards. Adult bustards, previously vaccinated with inactivated vaccine, should be vaccinated annually with inactivated vaccine. Juvenile bustards should receive a second dose of inactivated vaccine 4-6 mo after the first dose of inactivated vaccine. Even though inactivated PMV-1 vaccines induced hemagglutination inhibition antibodies and produced no adverse reactions, further studies will be required to determine the protective efficacy of the antibody.
对成年阿拉伯鸨（Chlamydotis undulata）和幼年灰颈鹭鸨（Ardeotis kori）接种了四种市售的灭活及活禽1型副黏病毒（PMV-1）疫苗方案。通过血清血凝抑制试验评估疫苗接种后的免疫反应。对每只肌肉注射0.5毫升市售禽用灭活疫苗（0.15毫升/千克体重）的灰颈鹭鸨，未能产生血凝抗体，但在每只鸟皮下接种第二剂和第三剂2.0毫升疫苗（0.40 - 0.45毫升/千克）后，检测到低强度和持续时间短的抗体滴度。在随后的试验中，当通过眼内途径进行两次或四次活疫苗接种后，以1.0毫升/千克体重皮下接种灭活疫苗时，幼年灰颈鹭鸨产生了更高、更持久的抗体滴度。与接种两次活疫苗后再接种灭活疫苗的灰颈鹭鸨相比，接种四次活疫苗后再接种灭活疫苗的灰颈鹭鸨产生的抗体滴度更高、持续时间更长。接种灭活疫苗的灰颈鹭鸨的抗体滴度高于活疫苗接种后的抗体反应，且更持久。先前接种过灭活疫苗的阿拉伯鸨，接种一剂灭活疫苗加强针后，52周内平均抗体滴度维持在较高水平（≥log₂5）。作者建议，应给鸨类皮下注射1.0毫升/千克的灭活PMV-1疫苗。先前接种过灭活疫苗的成年鸨类，应每年接种灭活疫苗。幼年鸨类应在第一剂灭活疫苗接种后4 - 6个月接种第二剂灭活疫苗。尽管灭活的PMV-1疫苗诱导产生了血凝抑制抗体且未产生不良反应，但仍需进一步研究以确定抗体的保护效力。
